Quarterly Result28 Jul 2025, 08:19 pm
Astec Lifesciences Reports 30.3% Increase in Consolidated Total Income in Q1FY26
AI Summary
Astec Lifesciences Limited has announced its financial results for the first quarter ended June 30, 2025. The company reported a consolidated total income of Rs. 91.6 crore, a 30.3% increase over Q1FY25. The EBITDA loss reduced to Rs. 10.5 crore from Rs. 45.3 crore in the same period last year. The Chairman, Mr. N B Godrej, attributed the improvement to increased volumes and contribution in the enterprise and CDMO businesses.
Key Highlights
- Consolidated total income increased by 30.3% to Rs. 91.6 crore in Q1FY26
- Consolidated EBITDA loss reduced to Rs. 10.5 crore in Q1FY26 from Rs. 45.3 crore in Q1FY25
- Revenue in enterprise business increased by 68.2% and in CDMO business by 85.7%
- Write down of Inventories of INR 18.5 crore impacted the EBITDA loss in Q1 FY25